|
[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
|
[2] TERRAULT NA, LOK ASF, McMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatol, 2018, 67 (4) :1560-1599.
|
|
[3] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int, 2016, 10 (1) :1-98.
|
|
[4] European Association for the Study of the Liver. EASL 2017clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 67 (2) :370-398.
|
|
[5] HEATHCOTE EJ, MARCELLIN P, BUTI M, et al. Three year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J]. Gastroenterology, 2011, 140 (1) :132-143.
|
|
[6] MARCELLIN P, GANE E, BUTI M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open-label follow up study[J].Lancet, 2013, 381 (9865) :468-475.
|
|
[7] PETERSEN J, HEYNE R, MAUSS S, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B:A3-year prospective field practice study in Germany[J]. Dig Dis Sci, 2016, 61 (10) :3061-3071.
|
|
[8] CHEN YH, CAO QF, HONG QY, et al. Effect of tenofovir disoproxil fumarate on serum FGF-23, β2-MG, Cys-C and RBP level in patients with chronic hepatitis B[J]. Chin J Clin Pharmacol Ther, 2017, 22 (7) :799-804. (in Chinese) 陈勇华, 曹群奋, 洪琼怿, 等.替诺福韦酯治疗对慢性乙型肝炎患者血清FGF-23、β2-MG、Cys-C及RBP水平的影响[J].中国临床药理学与治疗学, 2017, 22 (7) :799-804.
|
|
[9] CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBe Ag-positive chronic hepatitis B virus infection:A randomized, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1 (3) :185-195.
|
|
[10] TONG MJ, PAN CQ, HAN SH, et al. An expert consensus for the management of chronic hepatitis B in Asian Americans[J]. Aliment Pharmacol Ther, 2018, 47 (8) :1181-1200.
|
|
[11] MURAKAMI E, WANG T, PARK Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy[J]. Antimicrob Agents Chemother, 2015, 59 (6) :3563-3569.
|
|
[12] BABUSIS D, PHAN TK, LEE WA, et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340[J]. Mol Pharm, 2013, 10 (2) :459-466.
|
|
[13] AGARWAL K, FUNG SK, NGUYEN TT, et al. Twenty-eight day safety, antiviral activity and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection[J]. J Hepatol, 2015, 62 (3) :533-540.
|
|
[14] RUANE PJ, DEJESUS E, BERGER D, et al. Antiviral activity, safety and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1 positive adults[J]. J Acquir Immune Defic, 2013, 63 (4) :449-455.
|
|
[15] Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review (s) [Z/OL].[2018-06-14]. https://www. accessdata. fda. gov/drugsatfda_docs/nda/2016/208464Orig1s000ClinPharmR. pdf
|
|
[16] GONZALES ZAMORA JA. Adverse effects of direct acting antivirals in HIV/HCV coinfected patients:A 4-year experience in Miami, Florida[J]. Diseases, 2018, 6 (2) :51.
|
|
[17] BONORA S, CALCAGNO A, TRENTALANGE A, et al. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults[J]. Expert Opin Pharmacother, 2016, 17 (3) :409-419.
|
|
[18] BAM RA, BIRKUS G, BABUSIS D, et al. Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+T-cells and macrophages from demographically diverse donors[J].Antivir Ther, 2014, 19 (7) :669-677.
|
|
[19] BUTI M, GANE E, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBe Ag-negative chronic hepatitis B virus infection:A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1 (3) :196-206.
|
|
[20] AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68 (4) :672-681.
|
|
[21] LAU GK, PIRATVISUTH T, LUO KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBe Ag-positive chronic hepatitis B[J]. N Engl J Med, 2005, 352 (26) :2682-2695.
|
|
[22] JAFRI SM, LOK AS. Antiviral therapy for chronic hepatitis B[J]. Clin Liver Dis, 2010, 14 (3) :425-438.
|
|
[23] CHEN CH, LIN CL, KAO CH. Association between chronic hepatitis B virus infection and risk of osteoporosis:A nationwide population-based and study[J]. Medicine (Baltimore) , 2015, 94 (50) :e2276.
|
|
[24] SETO WK, ASAHINA Y, BROWN TT, et al. Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection[J]. Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[25] FONG TL, LEE BT, TIEN A, et al. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide[J]. J Viral Hepat, 2019, 26 (5) :561-567.
|
|
[26] LIU Y, MILLER MD, KITRINOS KM. Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro[J]. Antiviral Res, 2017, 139 (3) :25-31.
|
|
[27] CATHCART AL, CHAN HL, BHARDWAJ N, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B[J]. Antimicrob Agents Chemother, 2018, 62 (10) :e01064-18.
|
|
[28] PARK ES, LEE AR, KIM DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 70 (6) :1093-1102.
|
|
[29] LIU Y, CHEN RJ, LI XD. The rt S106C+H126Y+D134E triple variant of hepatitis B virus has no direct association with tenofovir resistance in Chinese patients[C]. APASL, Feb20-24, 2019, Manila, Poster ID589.
|
|
[30] BAM RA, YANT SR, CIHLAR T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity[J]. Antivir Ther, 2014, 19 (7) :687-692.
|
|
[31] CUSTODIO JM, FORDYCE M, GARNER W, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment[J]. Antimicrob Agents Chemother, 2016, 60 (9) :5135-5140.
|
|
[32] KARRIS MY. Short communication:Resolution of tenofovir disoproxil fumarate induced Fanconi syndrome with switch to tenofovir alafenamide fumarate in a HIV-1 and hepatitis B coinfected patient[J]. AIDS Res Hum Retroviruses, 2017, 33 (7) :718-722.
|
|
[33] CUSTODIO JM, MA G, CUVIN J, et al. Pharmacokinetics and safety of tenofovir alafenamide in subjects with severe hepatic impairment[J]. J Hepatol, 2016, 64 (1 Suppl) :s594-s595.
|
|
[34] WONG GL, CHAN HL, MAK CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis[J]. Hepatol, 2013, 58 (5) :1537-1547.
|
|
[35] WU CY, LIN JT, HO HJ, et al. Association of nucleos (t) ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B:A nationwide cohort study[J]. Gastroenterology, 2014, 147 (1) :143-151.
|
|
[36] LIM YS, HAN SB, HEO NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine[J]. Gastroenterology, 2014, 147 (1) :152-161.
|
|
[37] CHOI J, KIM HJ, LEE J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B:A Korean nationwide cohort study[J]. JAMA Oncol, 2018, 5 (1) :30-36.
|
|
[38] MURATA K, ASANO M, MATSUMOTO A, etal. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues:A new potential target for HBV infection[J]. Gut, 2018, 67 (2) :362-371.
|
|
[39] ABUSHAHBA W, BALAN M, CASTANEDA I, et al. Antitumor activity of type I and type III interferons in BNL hepatoma model[J]. Cancer Immunol Immunother, 2010, 59 (7) :1059-1071.
|
|
[40] SATO A, OHTSUKI M, HATA M, et al. Antitumor activity of IFN-lambda in murine tumor models[J]. J Immunol, 2006, 176 (12) :7686-7694.
|
|
[41] GORDON SC, ZHOU YR, LI J, et al. Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U. S. Cohort[J]. J Hepatol, 2019, 70 (1 Suppl) :e147.
|
|
[42] KIM SU, SEO YS, LEE HA, et al. A multi-center study of entecavir vs. tenofovir on prognosis of treatment-nave chronic hepatitis B in the Republic of Korea[J]. J Hepatol, 2019.[Epub ahead of print]
|
|
[43] WONG GL, CHAN HL, TSE YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B[J]. J Hepatol, 2018, 69 (4) :793-802.
|
|
[44] SETO WK, LO YR, PAWLOTSKY JM. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392 (10161) :2313-2324.
|
|
[45] YUEN MF, AGARWAL K, GANE E, et al. Assembly biosciences presents interim data from two phase 2a studies of ABI-H0731 in HBV-infected subjects in a late-breaker oral session at EASL 2019[J]. J Hepatol, 2019, 70 (1 Suppl) :e81-e132.
|
|
[46] YUEN MF, LOCARNINI S, LIM TH, et al. PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBs Ag <100 IU/ml threshold[J]. J Hepatol, 2019, 70 (1 Suppl) :e51-e52.
|
DownLoad: